8 completed. 8 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Completed 8 |
Follow Lethargy: new trials by email Literature Review of Lethargy trials Research Report on Lethargy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Repetitive Transcranial Magnetic Stimulation for Apathy in Alzheimer's Dementia Neurostar repetitive transcranial magnetic stimulator - Apathy, Alzheimer's Dementia | Phase 4 | Completed | Central Arkansas Veterans Healthcare System | 20 | 2014-05-01 | 2019-08-21 |
| Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy Rotigotine, Placebo - Idiopathic Parkinson's Disease | Phase 4 | Completed | UCB BIOSCIENCES GmbH | 122 | 2013-02-01 | 2018-08-31 |
| A Study of Patients With Major Depressive Disorder and Residual Apathy Duloxetine, Escitalopram - Major Depressive Disorder | Phase 4 | Completed | Eli Lilly and Company | 483 | 2009-09-01 | 2011-12-13 |
| Rasagiline and Apathy in Parkinson's Disease Rasagiline - Parkinson's Disease | Phase 4 | Completed | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 40 | 2008-09-01 | 2015-08-10 |
| Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study Methylphenidate, Placebo - Alzheimer's Disease, Apathy | Phase 4 | Completed | VA Office of Research and Development | 60 | 2007-08-01 | 2015-11-20 |
| Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults Memantine, Placebo - Depression | Phase 4 | Completed | Eric Lenze | 35 | 2005-08-01 | 2018-01-17 |
| Wellbutrin XL Effects on SSRIs Induced Changes Wellbutrin XL - Depression, Side Effects | Phase 4 | Completed | Indiana University | 15 | 2004-07-01 | 2007-10-16 |
| Apathy Associated With Alzheimer's Disease Dextroamphetamine, Methylphenidate - Dementia, Alzheimer Disease | Phase 4 | Completed | Sunnybrook Health Sciences Centre | 40 | 2003-10-01 | 2017-04-28 |
Alzheimer Disease (3) · Dementia (2) · Depression (2) · Depressive Disorder, Major (2) · Parkinson Disease (2) · Sexual Dysfunction, Physiological (1)
Nervous System Diseases (8) · Neurobehavioral Manifestations (8) · Neurologic Manifestations (8) · Pathological Conditions, Signs and Symptoms (8) · Signs and Symptoms (8) · Brain Diseases (5) · Central Nervous System Diseases (5) · Mental Disorders (5) · Neurodegenerative Diseases (5) · Neurocognitive Disorders (3) · Tauopathies (3) · Basal Ganglia Diseases (2) · Behavior (2) · Behavioral Symptoms (2) · Depressive Disorder (2)
Methylphenidate (2) · Bupropion (1) · Dextroamphetamine (1) · Duloxetine Hydrochloride (1) · Escitalopram (1) · Memantine (1) · rasagiline (1) · rotigotine (1)
Central Arkansas Veterans Healthcare System (1) · Eli Lilly and Company (1) · Eric Lenze (1) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) · Indiana University (1) · Sunnybrook Health Sciences Centre (1) · UCB BIOSCIENCES GmbH (1) · VA Office of Research and Development (1)
United States (5) · Canada (2) · Spain (2) · Australia (1) · Austria (1) · Hungary (1) · Mexico (1) · Poland (1) · Russia (1) · Slovakia (1) · Slovenia (1) · Taiwan (1)
Amit Anand, MD (1) · Eric J. Lenze, MD (1) · Jaime Kulisevsky, MD,PhD (1) · Krista L Lanctot, PhD (1) · Prasad R. Padala (1)
PMID 18591575, PMID 20220576, PMID 22173933, PMID 27267880, PMID 28945120, PMID 32925060
K23MH064196 (1)